Wall Street analysts expect IntriCon Co. (NASDAQ:IIN) to report earnings per share (EPS) of ($0.06) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for IntriCon’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.03). IntriCon reported earnings of $0.09 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 166.7%. The business is scheduled to report its next earnings report on Tuesday, February 18th.

On average, analysts expect that IntriCon will report full-year earnings of ($0.58) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.54). For the next fiscal year, analysts expect that the business will post earnings of $0.43 per share, with EPS estimates ranging from $0.23 to $0.58. Zacks’ EPS averages are an average based on a survey of analysts that cover IntriCon.

IntriCon (NASDAQ:IIN) last released its quarterly earnings results on Monday, November 4th. The technology company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.04). IntriCon had a positive return on equity of 1.81% and a negative net margin of 3.14%. The firm had revenue of $26.89 million for the quarter, compared to analyst estimates of $27.68 million.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised IntriCon from a “sell” rating to a “hold” rating in a research report on Saturday, January 4th. B. Riley set a $36.00 price target on IntriCon and gave the stock a “buy” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $32.00.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of IntriCon by 0.4% during the 2nd quarter. Vanguard Group Inc. now owns 420,572 shares of the technology company’s stock worth $9,825,000 after purchasing an additional 1,470 shares in the last quarter. Usca Ria LLC bought a new stake in shares of IntriCon during the 3rd quarter worth approximately $31,000. California Public Employees Retirement System raised its stake in shares of IntriCon by 5.8% during the 3rd quarter. California Public Employees Retirement System now owns 34,616 shares of the technology company’s stock worth $673,000 after purchasing an additional 1,900 shares in the last quarter. AdvisorNet Financial Inc bought a new stake in shares of IntriCon during the 3rd quarter worth approximately $46,000. Finally, Conestoga Capital Advisors LLC raised its stake in shares of IntriCon by 57.4% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 15,350 shares of the technology company’s stock worth $298,000 after purchasing an additional 5,600 shares in the last quarter. Institutional investors own 74.22% of the company’s stock.

NASDAQ:IIN traded up $0.01 during trading hours on Tuesday, reaching $18.48. 48,437 shares of the stock were exchanged, compared to its average volume of 68,669. IntriCon has a twelve month low of $16.81 and a twelve month high of $29.59. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.19 and a quick ratio of 2.33. The firm has a 50 day moving average of $18.29 and a 200 day moving average of $18.94. The stock has a market cap of $162.17 million, a PE ratio of -42.98, a PEG ratio of 3.68 and a beta of 0.65.

IntriCon Company Profile

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.

Recommended Story: S&P 500 Index

Get a free copy of the Zacks research report on IntriCon (IIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.